A 12-Week Multicentre, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Placebo in Patients > 6 years of age with EB simplex generalized severe
Latest Information Update: 10 Aug 2020
At a glance
- Drugs Ixekizumab (Primary)
- Indications Epidermolysis bullosa
- Focus Therapeutic Use
Most Recent Events
- 10 Aug 2020 Planned End Date changed to 22 May 2022.
- 09 Jun 2020 New trial record